Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Zheng, Xin ^a   Xing, Shan ^a   Liu, Xiao Min ^a   Liu, Wen ^a   Liu, Dan ^a   Chi, Pei Dong ^a   Chen, Hao ^a   Dai, Shu Qin ^a   Zhong, Qian ^a   Zeng, Mu Sheng ^a   Liu, Wan Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

ESCC; Esophageal cancer; YKL 40

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GLYCOPROTEIN; MESSENGER RNA; PROTEIN SCCA; PROTEIN YKL 40; TUMOR PROTEIN; UNCLASSIFIED DRUG; ADIPOCYTOKINE; CHI3L1 PROTEIN, HUMAN; LECTIN; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CARCINOMA CELL; CHEMOLUMINESCENCE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS DISEASE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SCCA BLOOD LEVEL; PROTEIN YKL 40 BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING; BLOOD; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; TUMOR CELL LINE; VERY ELDERLY;

ADIPOKINES; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LECTINS; MALE; MIDDLE AGED; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84903663339     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-490     Document Type: Article

References (37)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003, 349:2241-2252.
2. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001, 19:305-313.
3. Medical Research Council Oesophageal Cancer Working Group Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002, 359:1727-1733. Medical Research Council Oesophageal Cancer Working Group.
4. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007, 25:1160-1168.
5. Hu Y, Zheng B, Rong TH, Fu JH, Zhu ZH, Yang H, Luo KJ, Li YF. Prognostic analysis of the patients with stage-III esophageal squamous cell carcinoma after radical esophagectomy. Chin J Cancer 2010, 29:178-183.
6. Kawaguchi H, Ohno S, Miyazaki M, Hashimoto K, Egashira A, Saeki H, Watanabe M, Sugimachi K. CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer 2000, 89:1413-1417.
7. Mealy K, Feely J, Reid I, McSweeney J, Walsh T, Hennessy TP. Tumour marker detection in oesophageal carcinoma. Eur J Surg Oncol 1996, 22:505-507.
8. Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 1997, 79:1647-1655.
9. Dong J, Zeng BH, Xu LH, Wang JY, Li MZ, Zeng MS, Liu WL. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med 2010, 8:81.
10. Bleau G, Massicotte F, Merlen Y, Boisvert C. Mammalian chitinase-like proteins. EXS 1999, 87:211-221.
11. Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993, 32:949-955.
12. Stawerski P, Wagrowska-Danilewicz M, Stasikowska-Kanicka O, Danilewicz M. Increased tissue immunoexpression of YKL-40 protein in high grade serous ovarian cancers. Pathol Res Pract 2011, 207:573-576.
13. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients?. Cancer Epidemiol Biomarkers Prev 2006, 15:194-202.
14. Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol 2003, 38:599-605.
15. Zou L, He X, Zhang JW. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer. Braz J Med Biol Res 2010, 43(12):1232-1238.
16. Shao R, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer 2011, 105:1203-1209.
17. Thom I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, Bokemeyer C, Schumacher U, Laack E. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer 2010, 116:4114-4121.
18. Zhu CB, Chen LL, Tian JJ, Su L, Wang C, Gai ZT, Du WJ, Ma GL. Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery. Ann Surg Oncol 2012, 19:817-825.
19. Horbinski C, Wang G, Wiley CA. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. Int J Clin Exp Pathol 2010, 3:226-237.
20. Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W, Spriggs D, Fleisher M, Thaler H, Dupont J. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol 2007, 104:435-442.
21. Hogdall EV, Johansen JS, Kjaer SK, Price PA, Christensen L, Blaakaer J, Bock JE, Glud E, Høgdall CK. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep 2003, 10:1535-1538.
22. Johansen JS, Christensen IJ, Riisbro R, Greenall M, Han C, Price PA, Smith K, Brünner N, Harris AL. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat 2003, 80:15-21.
23. Choi IK, Kim YH, Kim JS, Seo JH. High serum YKL-40 is a poor prognostic marker in patients with advanced non-small cell lung cancer. Acta Oncol 2010, 49:861-864.
24. Xu CH, Yu LK, Hao KK. Serum YKL-40 Level Is Associated with the Chemotherapy Response and Prognosis of Patients with Small Cell Lung Cancer. PLoS One 2014, 9(5):e96384.
25. Zhang H, Jin Y, Chen X, Jin C, Law S, Tsao SW, Kwong YL. Cytogenetic aberrations in immortalization of esophageal epithelial cells. Cancer Genet Cytogenet 2006, 165:25-35.
26. Guo XZ, Zhang G, Wang JY, Liu WL, Wang F, Dong JQ, Xu LH, Cao JY, Song LB, Zeng MS. Prognostic relevance of Centromere protein H expression in esophageal carcinoma. BMC Cancer 2008, 8:233.
27. Yang GF, Cai PY, Li XM, Deng HX, He WP, Xie D. Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues. Ai Zheng 2009, 28:142-145.
28. Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue. Tumour Biol 2013, 35:277-286.
29. Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, Zhong JM, Wu HQ, Su Q, He YL, Zhan WH, Wen JM, Guan XY. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol 2009, 40:1790-1797.
30. Hogdall EV, Ringsholt M, Hogdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Moller L, Price PA, Christensen LH. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 2009, 9:8.
31. Radojicic J, Zaravinos A, Spandidos DA. HPV, KRAS mutations, alcohol consumption and tobacco smoking effects on esophageal squamous-cell carcinoma carcinogenesis. Int J Biol Markers 2012, 27:1-12.
32. Putz A, Hartmann AA, Fontes PR, Alexandre CO, Silveira DA, Klug SJ, Rabes HM. TP53 mutation pattern of esophageal squamous cell carcinomas in a high risk area (Southern Brazil): role of life style factors. Int J Cancer 2002, 98:99-105.
33. Taccioli C, Chen H, Jiang Y, Liu XP, Huang K, Smalley KJ, Farber JL, Croce CM, Fong LY. Dietary zinc deficiency fuels esophageal cancer development by inducing a distinct inflammatory signature. Oncogene 2012, 31:4550-4558.
34. Zhao Y, Schetter AJ, Yang GB, Nguyen G, Mathe EA, Li P, Cai H, Yu L, Liu F, Hang D, Yang H, Wang XW, Ke Y, Harris CC. microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer 2013, 132:2901-2909.
35. Zhou MQ, Du Y, Liu YW, Wang YZ, He YQ, Yang CX, Wang WJ, Gao F. Clinical and experimental studies regarding the expression and diagnostic value of carcinoembryonic antigen-related cell adhesion molecule 1 in non-small-cell lung cancer. BMC Cancer 2013, 13:359.
36. Liu Y, Huang Q, Liu W, Liu Q, Jia W, Chang E, Chen F, Liu Z, Guo X, Mo H, Chen J, Rao D, Ye W, Cao S, Hong M. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. Int J Cancer 2012, 131:406-416.
37. Munck-Wikland E, Kuylenstierna R, Wahren B, Lindholm J, Haglund S. Tumor markers carcinoembryonic antigen, CA 50, and CA 19-9 and squamous cell carcinoma of the esophagus. Pretreatment screening. Cancer 1988, 62:2281-2286.